Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

Turning Point Therapeutics Inc.

NAS: TPTX

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Turning Point Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Aug 9, 2022, 4:15 p.m.

TPTX
/zigman2/quotes/211319679/composite

$

75.04

Change

0.00 0.00%

Volume

Volume 12,756

Quotes are delayed by 20 min

/zigman2/quotes/211319679/composite

Previous close

$ 75.06

$ 75.04

Change

-0.02 -0.03%

Day low

Day high

$74.58

$75.14

Open

52 week low

52 week high

$23.77

$82.20

Open

Company Description

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS...

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

Valuation

Price to Sales Ratio

76.22

Price to Book Ratio

2.48

Enterprise Value to EBITDA

-11.76

Enterprise Value to Sales

454.64

Efficiency

Total Asset Turnover

0.03

Liquidity

Current Ratio

21.08

Quick Ratio

21.08

Cash Ratio

20.85

Profitability

Gross Margin

87.13

Operating Margin

-772.00

Pretax Margin

-767.30

Net Margin

-767.30

Return on Assets

-22.11

Return on Equity

-22.92

Return on Total Capital

-22.95

Capital Structure

Total Debt to Total Assets

0.56

Officers and Executives

Name Age Officer Since Title
Dr. Athena Countouriotis 49 2018 Chief Medical Officer & Executive Vice President
Ms. Miriam Cruz - 2018 Vice President-Clinical Operations
Mr. Paolo Tombesi 56 2021 Executive VP, Chief Financial & Accounting Officer
Dr. Mohammad Hirmand 50 - Chief Medical Officer & Executive Vice President
Mr. Ed Gemo - - Chief Information Officer & Senior Vice President

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/31/2022 Steve M Sabus
SVP & Chief Commercial Officer 		36,667   Award at $0 per share. 0
04/11/2022 Brian Sun
SVP & General Counsel 		45,000   Award at $0 per share. 0
02/09/2022 Athena M. Countouriotis
President & CEO; Director 		62,400   Award at $0 per share. 0
02/09/2022 Mohammad Hirmand
EVP & Chief Medical Officer 		15,000   Award at $0 per share. 0
02/09/2022 Mohammad Hirmand
EVP & Chief Medical Officer 		18,983   Award at $0 per share. 0
02/09/2022 Andrew Partridge
EVP & Chief Commercial Officer 		16,283   Award at $0 per share. 0
02/09/2022 Paolo Tombesi
EVP & Chief Financial Officer 		16,283   Award at $0 per share. 0
02/09/2022 Annette C. North
EVP & General Counsel 		16,283   Award at $0 per share. 0
02/09/2022 Siegfried Reich
EVP & Chief Scientific Officer 		13,567   Award at $0 per share. 0
02/09/2022 Athena M. Countouriotis
President & CEO; Director 		2,971   Disposition at $36.3 per share. 107,847
02/09/2022 Mohammad Hirmand
EVP & Chief Medical Officer 		669   Disposition at $36.3 per share. 24,284
02/09/2022 Andrew Partridge
EVP & Chief Commercial Officer 		221   Disposition at $36.3 per share. 8,022
02/09/2022 Annette C. North
EVP & General Counsel 		669   Disposition at $36.3 per share. 24,284
02/09/2022 Siegfried Reich
EVP & Chief Scientific Officer 		397   Disposition at $36.3 per share. 14,411
08/30/2021 Annette C. North
EVP & General Counsel 		10,000   Disposition at $80 per share. 800,000
08/30/2021 Annette C. North
EVP & General Counsel 		10,000   Derivative/Non-derivative trans. at $17 per share. 170,000
07/26/2021 Paolo Tombesi
EVP & Chief Financial Officer 		13,600   Award at $0 per share. 0
07/14/2021 Andrew Partridge
EVP & Chief Commercial Officer 		1,869   Disposition at $74.9 per share. 139,988
06/21/2021 Mark J. Alles
Director 		2,000   Acquisition at $81.34 per share. 162,680
06/15/2021 Annette C. North
EVP & General Counsel 		6,634   Disposition at $77.82 per share. 516,257
06/15/2021 Annette C. North
EVP & General Counsel 		2,700   Disposition at $77.37 per share. 208,899
06/15/2021 Annette C. North
EVP & General Counsel 		5,666   Disposition at $75.94 per share. 430,276
06/15/2021 Annette C. North
EVP & General Counsel 		15,000   Derivative/Non-derivative trans. at $17 per share. 255,000
05/06/2021 Annette C. North
EVP & General Counsel 		5,882   Derivative/Non-derivative trans. at $17 per share. 99,994
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		100   Disposition at $104.17 per share. 10,417
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		3,890   Disposition at $102.84 per share. 400,047
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		8,061   Disposition at $102.23 per share. 824,076
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		5,010   Disposition at $100.98 per share. 505,909
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		1,996   Disposition at $100.07 per share. 199,739
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		4,459   Disposition at $98.76 per share. 440,370
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		4,919   Disposition at $97.89 per share. 481,520
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		10,688   Derivative/Non-derivative trans. at $7.43 per share. 79,411
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		4,545   Derivative/Non-derivative trans. at $5.12 per share. 23,270
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		1,298   Derivative/Non-derivative trans. at $3.2 per share. 4,153
03/23/2021 Brian L. Baker
SVP of Finance and Admin. 		11,904   Derivative/Non-derivative trans. at $2.19 per share. 26,069
/news/latest/company/us/tptx

MarketWatch News on TPTX

  1. Seven reasons the beleaguered biotech sector is now a ‘buy’

    8:43 a.m. June 21, 2022

    - Michael Brush

  2. 5 Healthcare Stocks That Are Bucking the Bear Market

    4:46 a.m. June 16, 2022

    - Barron's Online

  4. Stocks Drop After Jobs Report

    4:24 p.m. June 3, 2022

    - Barron's Online

  7. Bristol Myers to pay $76 for each Turning Point share, a 122.5% premium

    7:04 a.m. June 3, 2022

    - Tomi Kilgore

  8. Bristol Myers to buy Turning Point Therapeutics in a deal valuing Turning Point at about $3.8 bln

    7:03 a.m. June 3, 2022

    - Tomi Kilgore

  9. Turning Point Therapeutics started at buy with $58 stock price target at BofA Securities

    10:25 a.m. May 20, 2022

    - Tomi Kilgore

  10. Turning Point Therapeutics stock price target cut to $53 from $75 at Stifel Nicolaus

    6:53 a.m. Oct. 15, 2021

    - Tomi Kilgore

  11. Turning Point Therapeutics stock price target cut to $125 from $166 at Wedbush

    7:24 a.m. Oct. 8, 2021

    - Tomi Kilgore

  12. Turning Point Therapeutics initiated at hold with $75 target price at Stifel

    7:08 a.m. Sept. 30, 2021

    - Tonya Garcia

  13. 4 Midsize Biotech Stocks That Have Breakout Potential

    10:02 a.m. Sept. 23, 2021

    - Barron's Online

  14. W.R. Grace and ThredUp See Activist Action

    9:30 p.m. April 9, 2021

    - Barron's Online

  15. Turning Point Therapeutics stock price target raised to $116 from $77 at SVB Leerink

    5:59 a.m. Oct. 26, 2020

    - Tomi Kilgore

  16. Cancer Meeting Could Ignite These Biotech Stocks

    6:00 a.m. Oct. 24, 2020

    - Barron's Online

  17. A Big Boost in Earnings Estimates for Nvidia

    9:30 p.m. Aug. 21, 2020

    - Barron's Online

  18. Turning Point Therapeutics started at outperform with $90 stock price target at Oppenheimer

    7:04 a.m. July 10, 2020

    - Tomi Kilgore

  19. Turning Point Therapeutics started at outperform with $63 stock price target at Wedbush

    8:24 a.m. Sept. 10, 2019

    - Tomi Kilgore

  20. The 4 Best IPOs So Far This Year

    5:30 a.m. Sept. 3, 2019

    - Barron's Online

  21. Loading more headlines...
/news/nonmarketwatch/company/us/tptx

Other News on TPTX

  1. 10-Q: TURNING POINT THERAPEUTICS, INC.

    4:30 p.m. Aug. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. Top 5 2nd Quarter Trades of QCM Cayman, Ltd.

    1:00 p.m. July 27, 2022

    - GuruFocus.com

  10. Pharma Is Place to Hide During Recession

    6:35 a.m. July 14, 2022

    - David Wainer

  11. Health Care falls 2.8% in June, Nutex, CureVac biggest losers

    12:23 p.m. July 1, 2022

    - Seeking Alpha

  12. Health Care falls 6.3% for Q2; MSP Recovery, GoodRx top losers

    11:59 a.m. July 1, 2022

    - Seeking Alpha

  13. Big Pharma Won’t Bail Out Battered Biotech

    7:00 a.m. June 30, 2022

    - David Wainer

  14. Bristol-Myers Squibb: Look For The Exit

    6:56 p.m. June 28, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Turning Point Therapeutics, Inc.

10628 Science Center Drive

Suite 200

San Diego, California 92121

Phone

1 8589265251

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$30.83M

Net Income

$-236.55M

Employees

250.00

Annual Report for TPTX

/news/pressrelease/company/us/tptx

Press Releases on TPTX

  3. Bristol Myers Squibb Announces Extension of Turning Point Tender Offer

    6:59 a.m. July 19, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.